EGFR and non-small cell lung carcinoma: In the FLAURA trial, osimertinib prolonged progression‐free survival (PFS) and overall survival (OS) compared with first‐generation EGFR TKIs such as gefitinib or erlotinib in patients with previously untreated EGFR‐positive NSCLC.6